Sharemaestro Newsreel

Haleon plc (HLN) Finalizes £500 Million Share Buyback After Cancelling 1,569,800 Shares in August 2026

Haleon plc has completed its £500 million share repurchase program, initially announced on March 12, 2026. The company repurchased and cancelled 1,569,800 ordinary shares on August 17 and 18, 2026, bringing the total shares cancelled year-to-date to 144,012,239. This action reduces the number of …

BMO initiates Exelixis stock at Market Perform, cites patent cliff

BMO Capital initiated coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and a $54.00 price target, citing concerns about a patent cliff in early 2030 for its main drug, cabozantinib. While the company's financial health is strong, BMO remains cautious as the follow-up …

JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL

JLB & Associates Inc. has purchased 48,849 shares of Exelixis, Inc. (NASDAQ:EXEL) for approximately $2.66 million, marking a new position in the biotechnology company. Institutional investors and hedge funds collectively own a significant 85.27% of Exelixis, which recently reported strong quarterly earnings exceeding estimates, …

Novo Nordisk Begins New Study Testing Smaller Doses Of Blockbuster Wegovy – A Look At Some Key Highlights

Novo Nordisk has initiated a new late-stage study to test smaller doses of its weight-loss drug, Wegovy, in pill form. The study aims to identify the most effective lower dose for patients with obesity or excess weight, potentially offering greater flexibility and improved tolerability …

electroCore (ECOR) Results Check: EPS Beats Its Estimate in the Latest Reading; Price Move

IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com

IDEAYA Biosciences Inc. has announced a clinical collaboration with Genentech to evaluate IDE892 in combination with GDC-7035 for patients with pancreatic ductal adenocarcinoma who have both an MTAP-deletion and a KRAS G12D mutation. This trial targets a subset of pancreatic cancer patients who currently …

Rice Hall James & Associates LLC Purchases Shares of 103,010 Simulations Plus, Inc. $SLP

Rice Hall James & Associates LLC recently acquired 103,010 shares of Simulations Plus, Inc. (NASDAQ:SLP) worth approximately $1.89 million, representing 0.51% of the company. Institutional investors now own 78.08% of the stock. Despite the institutional interest, analysts maintain a "Reduce" rating for Simulations Plus, …

BTIG raises Avita Medical stock price target on positive trial data

BTIG has increased its price target for Avita Medical (NASDAQ:RCEL) to $11.00 from $7.00, maintaining a Buy rating, following positive results from the company's PermeaDerm-I study. This study demonstrated a significant economic advantage over allograft and comparable clinical outcomes, with PermeaDerm and Cohealyx expected …

Summit Creek Advisors LLC Makes New $7.60 Million Investment in HealthEquity, Inc. $HQY

Summit Creek Advisors LLC has made a new $7.60 million investment in HealthEquity, Inc. (NASDAQ:HQY), purchasing 84,157 shares and making it their ninth-largest holding. HealthEquity reported strong quarterly earnings, beating analyst estimates with EPS of $1.24 and a 7.2% year-over-year revenue increase. The company …

Twist Bioscience selected as evaluator for Anthropic AI protein design project

Twist Bioscience Corporation (NASDAQ:TWST) has been chosen as an independent evaluator for Anthropic's multi-arm protein design campaign, utilizing Anthropic's AI models, Claude Opus 4.8 and Mythos Preview. Twist Bioscience will rapidly produce and test the AI-designed proteins for binding properties. This announcement follows Twist …

Form 8K Twist Bioscience Corp For: 19 August By Investing.com

This article reports on the filing of a Form 8K by Twist Bioscience Corp on August 19. It provides the title of the filing and notes that Investing.com is the source. The article itself is very brief, serving primarily as a notification of the …

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Elutia Inc. has completed the sale of its SimpliDerm® human acellular dermal matrix business for up to $11 million, including $8 million upfront. This divestiture provides non-dilutive capital and allows Elutia to concentrate resources on its proprietary drug-eluting biomatrix, NXT-41x, which is designed to …

Heartflow CEO John Farquhar sells $607,773 in company stock

Heartflow CEO John Farquhar sold 15,560 shares of company stock for $607,773 on August 14, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, HTFL shares increased by 16% to $45.23, trading near their 52-week high. This transaction occurred after HeartFlow …

Perigon Wealth Management LLC Invests $878,000 in Waystar Holding Corp. $WAY

Perigon Wealth Management LLC has invested $878,000 in Waystar Holding Corp. by acquiring 42,770 shares during the second quarter. This move aligns with several other institutional investors increasing their positions in Waystar. Despite an insider sale by CEO Matthew J. Hawkins, analysts maintain a …

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold"

Royal Bank of Canada downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from "moderate buy" to "hold," and Cantor Fitzgerald also shifted to a neutral rating. This follows the company's DURAVYU trial missing its primary endpoint, leading to a sharp stock decline and concerns about its future regulatory …

ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks

This article lists various ETFs that hold stocks of Jazz Pharmaceuticals Public Limited Company (J7Z). It provides detailed information for each ETF, including market value, weight of J7Z stock, issuer, management style, focus, expense ratio, assets under management (AUM), current price, percentage change, relative …

Inspire Medical Systems (NYSE:INSP) Stock Rating Upgraded by Zacks Research

Zacks Research has upgraded Inspire Medical Systems (NYSE:INSP) from a "hold" to a "strong-buy" rating. Despite this, the consensus among analysts remains "hold" with an average price target of $66.19. The company recently reported quarterly earnings of $0.14 per share, significantly exceeding estimates, and …

Trv Gp Vi LLC Takes Position in Rapport Therapeutics, Inc. $RAPP

Trv Gp Vi LLC recently acquired a significant stake in Rapport Therapeutics (NASDAQ:RAPP), purchasing 969,218 shares valued at approximately $40.4 billion, making it the third largest holding in their portfolio. Despite this, the company reported a quarterly loss and experienced insider stock sales. Analysts …

Sintx Technologies, Inc. SEC Filing (Aug 19, 2026)

Sintx Technologies, Inc. (SINT) has filed an EFFECT form with the SEC, indicating a Notice of Effectiveness for an S-3 Shelf Registration Statement, which became effective on August 18, 2026, at 4:30 P.M. The filing was accepted by SEC EDGAR on August 19, 2026, …

So-Young to Report Second Quarter 2026 Financial Results on August 31, 2026

So-Young International Inc. (NASDAQ: SY) announced it will report its financial results for the second quarter ended June 30, 2026, before U.S. markets open on August 31, 2026. Management will host an earnings conference call on the same day at 7:30 AM U.S. Eastern …

4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC

Trv Gp Vi LLC has acquired over 4.2 million shares of Septerna, Inc. (NASDAQ:SEPN) valued at approximately $141 million, making it their largest portfolio holding with a 9.34% stake. This acquisition comes amidst positive analyst sentiment, with an average "Moderate Buy" rating and a …

Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN

Trv Gp V LLC has acquired a significant new position in Septerna, Inc. (NASDAQ:SEPN) during the second quarter, making it their second-largest holding. Other institutional investors like BlackRock and Goldman Sachs have also increased their stakes, indicating growing institutional interest. Despite some insider selling, …

TriSalus (TLSI) Latest Quarter: The Bottom-Line Figure Trails Its Comparison for This Review; Price Move: Shares Finish 2.47% Up in the Current Update - Segment Revenue Breakdown

BioRestorative Therapies Inc expected to post a loss of 12 cents a share - Earnings Preview

BioRestorative Therapies Inc (BRTX) is projected to report a loss of 12 cents per share. This earnings preview indicates the company's financial outlook for an upcoming report. The full article provides more details on this prediction.

Quanterix (QTRX) CCO files initial ownership report with no shares

James Edward Gute Jr., Chief Commercial Officer of Quanterix Corp (QTRX), has filed an initial statement of beneficial ownership of securities (Form 3) with no current reportable holdings or transactions in Quanterix Corp securities. This filing indicates that as of the report date, he …

Quanterix (QTRX) director now holds 162,401 shares

Quanterix Corp (QTRX) director William P. Donnelly reported the vesting and conversion of 2,802 restricted stock units (RSUs) into common stock on August 17, 2026. Following this transaction, Donnelly directly holds 162,401 shares of Quanterix common stock. The RSUs were originally granted on August …

Wealthfront Advisers LLC Buys Shares of 42,108 Cencora, Inc. $COR

Wealthfront Advisers LLC has acquired a new stake of 42,108 shares in Cencora, Inc. (NYSE:COR) during the second quarter, valued at approximately $11.9 million. This purchase is part of broader institutional investment, with 97.52% of Cencora's stock owned by institutional investors and hedge funds. …

Moderna Stock Soars 100% after “Landmark” Phase 3 Cancer Trial Win in Melanoma

Moderna's stock surged by 100% in pre-market trading following positive Phase 3 trial results for its personalized cancer treatment for melanoma, developed with Merck. The therapy, combining Moderna’s mRNA-4157 with Merck’s Keytruda, demonstrated significant improvements in recurrence-free survival and distant metastasis-free survival. This marks …

Meeder Advisory Services Inc. Acquires Shares of 5,936 HCA Healthcare, Inc. $HCA

Meeder Advisory Services Inc. has purchased a new stake of 5,936 shares in HCA Healthcare, Inc. (NYSE:HCA) valued at approximately $2.314 million during the second quarter. Other institutional investors have also adjusted their positions in HCA Healthcare. The company recently announced a quarterly dividend …

Quanterix files Form 3 for Chief Commercial Officer James Edward Gute Jr

Quanterix has filed a Form 3 for James Edward Gute Jr., officially naming him as Chief Commercial Officer. The filing was dated August 17, 2026. This news brief was generated by AI based on information from the SEC's EDGAR system.

Accendra (ACH) Quarterly Figures: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Stock Move: The Stock Gains 5.61% for the Current Session - Basic EPS Analysis

MDxHealth (MDXH) Earnings Update: EPS Prints Above Forecast in Latest Trading; Post-Report: The Stock Ends Down 12.20% in the Available Record - Margin Guidance

Cartesian (RNAC) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison in the Latest Session; Closing Reaction: The Stock Gains 0.22% at the Close - Return On Capital

Assembly (ASMB) Results Check: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Stock Move: The Market Price Advances 7.06% at the Close - Net Income Trends

Summit Creek Advisors LLC Takes Position in Hinge Health Inc. $HNGE

Stryker Corporation $SYK Stock Holdings Trimmed by JLB & Associates Inc.

JLB & Associates Inc. reduced its stake in Stryker Corporation (NYSE:SYK) by 18.6% in the second quarter, now holding 21,723 shares valued at $6.84 million. Other institutional investors adjusted their positions, with some increasing and others decreasing holdings. The article also covers analyst ratings, …